Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company primary areas of focus include HIV, AIDS, liver disease, and serious cardiovascular and respiratory conditions.
Website: gilead.com



Growth: Pretty weak revenue growth rate 4.7%, there is acceleration compared to average historical growth rates 2.6%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of +41.1%

Profitability: LTM EBITDA margin is positive, +30.5%. On average the margin is decreasing unsteadily. In the last quarter the company did not beat the estimated EPS, -11.0%. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.17 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 2.0%. Free cash flow yield 0.3% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 148.0% higher than minimum and -0.5% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 3.1x by EV / Sales multiple , the company can be 50.3% overvalued

Insiders: For the last 3 months insiders sold company shares on $44.1 mln (-0.025% of cap.)

Key Financials (Download financials)

Ticker: GILD
Share price, USD:  (+3.2%)156.64
year average price 115.89  


year start price 104.08 2025-02-14

min close price 96.91 2025-05-09

max close price 155.80 2026-02-11

current price 156.64 2026-02-13
Common stocks: 1 254 309 967

Dividend Yield:  2.0%
FCF Yield LTM: 0.3%
EV / LTM EBITDA: 20.7x
EV / EBITDA annualized: 17.8x
Last revenue growth (y/y):  +4.7%
Last growth of EBITDA (y/y):  -15.6%
Historical revenue growth:  +2.6%
Historical growth of EBITDA:  +14.9%
EV / Sales: 6.3x
Margin (EBITDA LTM / Revenue): 30.5%
Fundamental value created in LTM:
Market Cap ($m): 196 475
Net Debt ($m): -10 605
EV (Enterprise Value): 185 870
Price to Book: 8.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-05zacks.com

Should You Buy, Hold, or Sell GILD Stock Ahead of Q4 Earnings?

2026-02-04zacks.com

Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts

2026-02-01defenseworld.net

Atle Fund Management AB Purchases 5,004 Shares of Gilead Sciences, Inc. $GILD

2026-01-30zacks.com

Gilead Sciences (GILD) Advances While Market Declines: Some Information for Investors

2026-01-22zacks.com

Why Gilead Sciences (GILD) Outpaced the Stock Market Today

2026-01-21businesswire.com

New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer

2026-01-16seekingalpha.com

Gilead: A Top GARP Biotech Play, But Momentum Weakens (Downgrade)

2026-01-12seekingalpha.com

Gilead Sciences: From All-Time Highs To Higher Highs

2026-01-12seekingalpha.com

Gilead Sciences, Inc. (GILD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2026-01-02marketbeat.com

3 Cash-Flow Machines Investors May Want Heading Into 2026
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol GILD GILD GILD GILD GILD GILD GILD GILD GILD GILD GILD GILD GILD GILD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 882 095 882 095 882 095 882 095 882 095 882 095 882 095 882 095 882 095 882 095 882 095 882 095 882 095 882 095
fillingDate 2025-11-07 2025-08-07 2024-11-12 2024-08-08 2024-05-08 2023-11-07 2023-08-04 2023-05-03 2022-11-02
acceptedDate 2025-11-07 16:08:32 2025-08-07 17:14:25 2025-02-28 16:21:03 2024-11-12 08:36:10 2024-08-08 17:17:59 2024-05-08 16:58:20 2024-02-23 16:44:27 2023-11-07 17:18:43 2023-08-04 16:06:43 2023-05-03 16:06:40 2023-02-22 16:18:52 2022-11-02 17:02:58 2022-02-23 16:55:27 2021-02-25 16:15:23
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 7 769M 7 081M 28 754M 7 545M 6 949M 6 686M 27 116M 7 050M 6 599M 6 352M 27 281M 7 042M 27 305M 24 689M
costOfRevenue 1 569M 1 501M 6 251M 1 574M 1 544M 1 552M 6 498M 1 565M 1 442M 1 401M 5 657M 1 395M 6 601M 4 572M
grossProfit 6 200M 5 580M 22 503M 5 971M 5 405M 5 134M 20 618M 5 485M 5 157M 4 951M 21 624M 5 647M 20 704M 20 117M
grossProfitRatio 0.798 0.788 0.791 0.778 0.768 0.778 0.781 0.779 0.802
researchAndDevelopmentExpenses 1 346M 1 491M 5 907M 1 395M 1 348M 1 470M 5 718M 1 457M 1 407M 1 447M 4 977M 1 149M 4 601M 5 039M
generalAndAdministrativeExpenses 0 501M 2 638M 0 0 0 2 818M 0 0 0 4 895M 0 4 511M 4 317M
sellingAndMarketingExpenses 0 864M 3 453M 0 0 0 3 272M 0 0 0 778M 0 735M 795M
sellingGeneralAndAdministrativeExpenses 1 357M 1 365M 6 091M 1 433M 1 369M 1 362M 6 090M 1 315M 1 849M 1 319M 5 673M 1 213M 5 246M 5 112M
otherExpenses 170M 250M 8 843M 2 255M -355M 91M 1 205M -72M 152M -174M 3 644M 0 939M 5 895M
operatingExpenses 2 873M 3 106M 20 841M 5 083M 2 717M 2 832M 13 013M 2 772M 3 256M 2 766M 14 294M 2 362M 10 786M 16 046M
costAndExpenses 4 442M 4 607M 27 092M 6 657M 4 261M 4 384M 19 511M 4 337M 4 698M 4 167M 19 951M 3 757M 17 387M 20 618M
interestIncome 0 73M 281M 52M 0 0 376M 232M 0 0 106M 0 0 0
interestExpense 256M 254M 977M 237M 237M 254M 944M 232M 230M 230M 935M 229M 1 001M 984M
depreciationAndAmortization 686M 691M 2 767M 690M 694M 690M 2 693M 18M 389M 306M 2 103M 797M 2 050M 1 480M
ebitda 4 583M 3 374M 4 434M 1 884M 2 983M 2 992M 10 496M 2 641M 2 054M 2 011M 8 852M 3 634M 11 329M 4 133M
ebitdaratio 0.59 0.476 0.25 0.487 0.448 0.375 0.311 0.317 0.516
operatingIncome 3 327M 2 474M 1 662M 888M 2 688M 2 302M 7 605M 2 623M 1 665M 1 705M 7 330M 2 837M 9 918M 4 071M
operatingIncomeRatio 0.428 0.349 0.118 0.387 0.344 0.372 0.252 0.268 0.403
totalOtherIncomeExpensesNet 314M -45M -972M 68M -635M -6 788M -746M -163M -84M -405M -1 516M -405M -1 640M -2 402M
incomeBeforeTax 3 641M 2 429M 690M 956M 2 053M -4 486M 6 859M 2 318M 1 588M 1 300M 5 814M 2 432M 8 278M 1 669M
incomeBeforeTaxRatio 0.469 0.343 0.127 0.295 -0.671 0.329 0.241 0.205 0.345
incomeTaxExpense 589M 468M 211M -297M 438M -315M 1 247M 146M 549M 316M 1 248M 646M 2 077M 1 580M
netIncome 3 052M 1 960M 480M 1 253M 1 614M -4 170M 5 665M 2 180M 1 045M 1 010M 4 592M 1 789M 6 225M 123M
netIncomeRatio 0.393 0.277 0.166 0.232 -0.624 0.309 0.158 0.159 0.254
eps 2.46 1.57 0.38 1 1.29 -3.34 4.54 1.75 0.84 0.81 3.66 1.43 4.96 0.098
epsdiluted 2.43 1.56 1 1.29 -3.34 1.73 0.83 0.8 1.42
weightedAverageShsOut 1 243M 1 245M 1 247M 1 247M 1 247M 1 247M 1 248M 1 248M 1 249M 1 248M 1 255M 1 255M 1 256M 1 257M
weightedAverageShsOutDil 1 254M 1 255M 1 255M 1 254M 1 251M 1 247M 1 258M 1 257M 1 258M 1 261M 1 262M 1 261M 1 262M 1 263M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-23 2023-02-22 2022-02-23 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -696M -568M -829M -1 001M -984M
ebit 1 667M 7 803M 6 749M 9 279M 2 653M
nonOperatingIncomeExcludingInterest -5M -198M 581M 639M 1 418M
netIncomeFromContinuingOperations 479M 5 612M 4 566M 6 201M 89M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 1 000 000 1 000 000 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome 480M 5 665M 4 592M 6 225M 123M
epsDiluted 0.38 4.5 3.64 4.93 0.097

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol GILD GILD GILD GILD GILD GILD GILD GILD GILD GILD GILD GILD GILD GILD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 882 095 882 095 882 095 882 095 882 095 882 095 882 095 882 095 882 095 882 095 882 095 882 095 882 095 882 095
fillingDate 2025-11-07 2025-08-07 2024-11-12 2024-08-08 2024-05-08 2023-11-07 2023-08-04 2023-05-03 2022-11-02
acceptedDate 2025-11-07 16:08:32 2025-08-07 17:14:25 2025-02-28 16:21:03 2024-11-12 08:36:10 2024-08-08 17:17:59 2024-05-08 16:58:20 2024-02-23 16:44:27 2023-11-07 17:18:43 2023-08-04 16:06:43 2023-05-03 16:06:40 2023-02-22 16:18:52 2022-11-02 17:02:58 2022-02-23 16:55:27 2021-02-25 16:15:23
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 7 330M 5 144M 9 991M 5 037M 2 772M 4 718M 6 085M 5 705M 5 704M 4 936M 5 412M 4 699M 5 338M 5 997M
shortTermInvestments 19M 69M 1 577M 5 037M 1 426M 1 341M 1 179M 1 159M 8 001M 936M 973M 961M 1 182M 1 411M
cashAndShortTermInvestments 7 349M 5 213M 11 568M 5 037M 4 198M 6 059M 7 264M 8 021M 8 001M 7 200M 6 385M 5 660M 6 520M 7 408M
netReceivables 5 095M 4 781M 4 420M 4 587M 4 663M 4 669M 4 660M 4 790M 4 229M 4 162M 4 777M 4 354M 4 493M 4 892M
inventory 1 785M 1 825M 1 710M 1 869M 2 026M 1 853M 1 787M 3 202M 3 181M 3 010M 1 507M 1 463M 1 618M 1 683M
otherCurrentAssets 3 645M 2 899M 995M 3 286M 2 856M 1 460M 2 374M 2 663M 1 758M 1 846M 0 2 077M 0 0
totalCurrentAssets 17 874M 14 718M 19 173M 14 779M 12 317M 14 041M 16 085M 16 013M 15 411M 14 372M 14 443M 13 554M 14 772M 15 996M
propertyPlantEquipmentNet 5 500M 5 459M 5 414M 5 391M 5 346M 5 321M 5 317M 5 572M 5 540M 5 479M 5 475M 5 349M 5 121M 4 967M
goodwill 8 314M 8 314M 8 314M 8 314M 8 314M 8 314M 8 314M 8 314M 8 314M 8 314M 8 314M 8 314M 8 332M 8 108M
intangibleAssets 17 969M 18 567M 19 948M 20 546M 22 832M 23 428M 26 454M 27 152M 27 750M 28 348M 28 893M 29 440M 33 455M 33 126M
goodwillAndIntangibleAssets 26 283M 26 881M 28 262M 28 860M 31 146M 31 742M 34 768M 35 466M 36 064M 36 662M 37 207M 37 754M 41 787M 41 234M
longTermInvestments 2 005M 1 913M 0 0 710M 1 146M 1 163M 1 156M 1 334M 1 327M 1 245M 1 282M 1 309M 502M
taxAssets 1 998M 2 721M 0 0 0 0 0 -1 156M -6 446M 0 0 0 0 0
otherNonCurrentAssets 4 873M 4 031M 6 146M 5 495M 4 060M 4 042M 4 792M 5 323M 10 434M 4 037M 4 800M 4 618M 4 963M 5 708M
totalNonCurrentAssets 40 659M 41 005M 39 822M 39 746M 41 262M 42 251M 46 040M 46 361M 46 926M 47 505M 48 727M 49 003M 53 180M 52 411M
otherAssets 0 -2M 0 0 0 0 0 -1 000 000 0 -1 000 000 1 000 000 0 0 0
totalAssets 58 533M 55 721M 58 995M 54 525M 53 579M 56 292M 62 125M 62 373M 62 337M 61 876M 63 171M 62 557M 67 952M 68 407M
accountPayables 808M 582M 833M 903M 537M 622M 550M 586M 622M 627M 905M 614M 705M 844M
shortTermDebt 2 806M 2 806M 1 815M 1 812M 1 810M 3 667M 1 798M 1 793M 4 037M 2 283M 2 273M 2 270M 1 516M 2 757M
taxPayables 0 0 830M 1 536M 1 265M 1 198M 1 208M 2 088M 2 610M 3 775M 959M 902M 539M 598M
deferredRevenue 0 0 0 0 738M -4 289M 0 2 088M -4 659M 0 0 0 0 0
otherCurrentLiabilities 8 683M 7 801M 3 818M 7 474M 7 169M 13 015M 3 922M 7 478M 13 964M 7 618M 3 622M 7 539M 1 426M 1 451M
totalCurrentLiabilities 12 297M 11 189M 12 004M 11 725M 10 781M 13 015M 11 280M 11 945M 13 964M 10 528M 11 238M 10 423M 11 610M 11 397M
longTermDebt 22 135M 22 140M 24 896M 21 437M 21 540M 21 527M 23 189M 24 113M 22 563M 24 233M 22 957M 22 953M 25 179M 28 645M
deferredRevenueNonCurrent 0 0 0 0 0 -26 755M 0 72M 64M 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 597M 652M 724M 794M 907M 933M 1 588M 1 984M 2 106M 2 401M 2 673M 3 036M 4 356M 3 914M
otherNonCurrentLiabilities 2 048M 2 149M 2 125M 2 180M 2 156M 30 117M 3 319M 2 017M 2 546M 3 775M 5 094M 28 193M 5 743M 6 230M
totalNonCurrentLiabilities 24 780M 24 941M 27 745M 24 411M 24 603M 25 822M 28 096M 28 186M 27 279M 30 409M 30 724M 31 077M 35 278M 38 789M
otherLiabilities 0 0 0 -1 000 000 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 0 0 0 0 1 395M 0 924M 1 354M 1 277M 0 0 0 0
totalLiabilities 37 077M 36 130M 39 749M 36 135M 35 384M 38 837M 39 376M 40 131M 41 243M 40 937M 41 962M 41 500M 46 888M 50 186M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 1 000 000 1 000 000 1 000 000 0 1 000 000 1 000 000 1 000 000 1 000 000 1 000 000 1 000 000 1 000 000 1 000 000 1 000 000 1 000 000
retainedEarnings 12 825M 11 325M 11 497M 11 073M 11 165M 10 656M 16 304M 16 002M 15 138M 15 223M 15 687M 15 756M 16 324M 14 381M
accumulatedOtherComprehensiveIncomeLoss 36M -18M 132M 73M 93M 69M 28M 31M 10M -20M 2M 98M 83M -60M
othertotalStockholdersEquity 8 678M 8 367M 7 328M 7 022M 6 813M 6 208M 5 945M 5 735M 5 226M
totalStockholdersEquity 21 540M 19 675M 19 330M 18 474M 18 281M 17 539M 22 833M 22 242M 21 094M 20 939M 21 240M 21 081M 21 069M 18 202M
totalEquity 21 456M 19 591M 19 246M 18 390M 18 197M 17 455M 22 749M 22 170M 21 030M 20 881M 21 209M 21 081M 21 064M 18 221M
totalLiabilitiesAndStockholdersEquity 58 533M 55 721M 54 525M 53 581M 56 292M 62 373M 62 337M 61 876M 62 557M
minorityInterest -84M -84M -84M -84M -84M -84M -84M -72M -64M -58M -31M 0 -5M 19M
totalLiabilitiesAndTotalEquity 58 533M 55 721M 58 995M 54 525M 53 581M 56 292M 62 125M 62 373M 62 337M 61 876M 63 171M 62 557M 67 952M 68 407M
totalInvestments 2 024M 1 982M 1 577M 5 037M 2 136M 2 487M 2 342M 2 315M 8 001M 2 263M 2 218M 2 243M 2 491M 1 913M
totalDebt 24 941M 24 946M 26 711M 23 249M 23 350M 25 194M 24 987M 25 906M 26 600M 26 516M 25 230M 25 223M 26 695M 31 402M
netDebt 17 611M 19 802M 16 720M 18 212M 20 578M 20 476M 18 902M 20 201M 20 896M 21 580M 19 818M 20 524M 21 357M 25 405M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-23 2023-02-22 2022-02-23 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 4 420M 4 660M 4 777M 4 493M 4 892M
otherReceivables 0 0 0 0 0
prepaids 480M 0 1 774M 2 141M 2 013M
totalPayables 2 479M 1 758M 1 864M 1 244M 1 442M
otherPayables 1 646M 1 208M 959M 539M 598M
accruedExpenses 3 892M 3 802M 3 479M 7 424M 5 747M
capitalLeaseObligationsCurrent 0 0 0 0 0
capitalLeaseObligationsNonCurrent 0 0 0 0 0
treasuryStock 0 0 0 0 0
additionalPaidInCapital 7 700M 6 500M 5 550M 4 661M 3 880M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol GILD GILD GILD GILD GILD GILD GILD GILD GILD GILD GILD GILD GILD GILD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 882 095 882 095 882 095 882 095 882 095 882 095 882 095 882 095 882 095 882 095 882 095 882 095 882 095 882 095
fillingDate 2025-11-07 2025-08-07 2024-11-12 2024-08-08 2024-05-08 2023-11-07 2023-08-04 2023-05-03 2022-11-02
acceptedDate 2025-11-07 16:08:32 2025-08-07 17:14:25 2025-02-28 16:21:03 2024-11-12 08:36:10 2024-08-08 17:17:59 2024-05-08 16:58:20 2024-02-23 16:44:27 2023-11-07 17:18:43 2023-08-04 16:06:43 2023-05-03 16:06:40 2023-02-22 16:18:52 2022-11-02 17:02:58 2022-02-23 16:55:27 2021-02-25 16:15:23
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 3 052M 1 960M 480M 1 253M 1 614M -4 170M 5 665M 2 172M 1 039M 985M 4 592M 1 786M 6 201M 123M
depreciationAndAmortization 686M 691M 2 767M 690M 694M 690M 2 693M 684M 681M 94M 2 103M 525M 2 050M 1 480M
deferredIncomeTax 659M -178M -1 844M -576M -166M -723M -962M -68M -221M -303M -1 552M -270M -116M -214M
stockBasedCompensation 230M 225M 835M 216M 210M 187M 766M 202M 198M 165M 644M 168M 635M 643M
changeInWorkingCapital -297M -2 014M -880M 642M -1 546M -459M -2 303M -1 549M 331M 136M -1 763M -117M 489M -1 638M
accountsReceivables -333M -292M 139M 95M -29M -66M 157M -612M -86M 635M -406M -372M 313M -1 171M
inventory -515M -175M -426M 115M -70M -45M -842M -82M -226M -227M -310M -95M 11M -195M
accountsPayables 230M -162M 290M 11M -83M 72M -347M -29M -3M -272M 226M 66M -118M 80M
otherWorkingCapital 321M -1 385M -883M 421M -1 364M -420M -1 271M -826M 646M -136M -1 273M 284M 283M -352M
otherNonCashItems -222M 143M 9 470M 2 084M 519M 8 300M 2 147M 315M 309M 667M 5 048M 771M 2 125M 7 774M
netCashProvidedByOperatingActivities 4 108M 827M 10 828M 4 309M 1 325M 2 219M 8 006M 1 756M 2 337M 1 744M 9 072M 2 863M 11 384M 8 168M
investmentsInPropertyPlantAndEquipment -147M -107M -523M -141M -130M -105M -585M -122M -139M -109M -728M -157M -579M -650M
acquisitionsNet -167M -21M -4 840M -570M -152M -4 043M -1 152M -79M -243M -551M -1 797M -448M -1 584M -25 742M
purchasesOfInvestments -352M -2 308M -736M -9M -34M -654M -2 372M -395M -645M -527M -1 942M -430M -3 897M -20 770M
salesMaturitiesOfInvestments 236M 310M 2 592M 0 0 2 592M 1 844M 361M 545M 491M 2 002M 324M 2 910M 32 718M
otherInvestingActivites 3M 10M 10M 9M 5M 6M -1 000 000 -130M -2M
netCashUsedForInvestingActivites -427M -2 116M -710M -307M -2 207M -229M -483M -826M -713M
debtRepayment -9M -9M -112M 0 0 -2 250M -1 068M 0 -1 000M
commonStockIssued 97M 27M 98M 5M 146M 83M 26M 97M 36M
commonStockRepurchased -435M -527M -1 150M -300M -100M -400M -1 000M -300M -150M -400M -1 396M -180M -546M -1 583M
dividendsPaid -1 005M -994M -1 962M -972M -990M -953M -944M -969M -929M
otherFinancingActivites -137M -64M 897M -1 886M -116M 1 902M 1 035M -134M -45M
netCashUsedProvidedByFinancingActivities -1 489M -1 567M -1 379M -2 953M -1 361M -1 518M -1 101M -1 406M -2 118M
effectOfForexChangesOnCash -5M 73M -40M 44M -11M -18M 57M -7M 14M 13M -63M -72M -35M 43M
netChangeInCash 2 186M -2 782M 3 906M 2 265M -1 946M -1 367M 673M 1 000 000 768M -476M 74M -40M -659M -5 634M
cashAtEndOfPeriod 7 330M 5 144M 9 991M 5 037M 2 772M 4 718M 6 085M 5 705M 5 704M 4 936M 5 412M 4 699M 5 338M 5 997M
cashAtBeginningOfPeriod 5 144M 7 926M 6 085M 2 772M 4 718M 6 085M 5 412M 5 704M 4 936M 5 412M 5 338M 4 739M 5 997M 11 631M
operatingCashFlow 4 108M 827M 10 828M 4 309M 1 325M 2 219M 8 006M 1 756M 2 337M 1 744M 9 072M 2 863M 11 384M 8 168M
capitalExpenditure -147M -107M -523M -141M -130M -105M -585M -122M -139M -109M -728M -157M -579M -650M
freeCashFlow 3 961M 720M 10 305M 4 168M 1 195M 2 114M 7 421M 1 634M 2 198M 1 635M 8 344M 2 706M 10 805M 7 518M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-23 2023-02-22 2022-02-23 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 58M 0 -1 000 000 19M -171M
netCashProvidedByInvestingActivities -3 449M -2 265M -2 466M -3 131M -14 615M
netDebtIssuance 1 494M -270M -1 500M -4 750M 5 684M
longTermNetDebtIssuance 1 494M -270M -1 500M -4 750M 5 684M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance -728M -768M -1 087M -377M -1 327M
netCommonStockIssuance -728M -768M -1 087M -377M -1 327M
commonStockIssuance 422M 232M 309M 169M 256M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid -3 918M -3 809M -3 709M -3 605M -3 449M
commonDividendsPaid -3 918M -3 809M -3 709M -3 605M -3 449M
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -281M -278M -173M -145M -138M
netCashProvidedByFinancingActivities -3 433M -5 125M -6 469M -8 877M 770M
incomeTaxesPaid 2 779M 3 990M 3 136M 2 509M 2 639M
interestPaid 951M 891M 907M 979M 951M

Earning call transcript

2025 q3
2025-10-30 ET (fiscal 2025 q3)
2025 q2
2025-08-07 ET (fiscal 2025 q2)
2025 q1
2025-04-24 ET (fiscal 2025 q1)
2024 q4
2025-02-11 ET (fiscal 2024 q4)
2024 q3
2024-11-06 ET (fiscal 2024 q3)
2024 q2
2024-08-08 ET (fiscal 2024 q2)
2024 q1
2024-04-25 ET (fiscal 2024 q1)
2023 q4
2024-02-06 ET (fiscal 2023 q4)
2023 q3
2023-11-07 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-04-27 ET (fiscal 2023 q1)
2022 q4
2023-02-02 ET (fiscal 2022 q4)
2022 q3
2022-10-27 ET (fiscal 2022 q3)
2022 q2
2022-08-02 ET (fiscal 2022 q2)
2022 q1
2022-04-28 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2026-02-10 16:02 ET
Gilead Sciences reported for 2025 q4
SEC form 8
2026-02-10 16:02 ET
Gilead Sciences published news for 2025 q4
SEC form 8
2025-10-30 20:04 ET
Gilead Sciences reported for 2025 q3
SEC form 8
2025-10-30 20:04 ET
Gilead Sciences published news for 2025 q3
SEC form 10
2025-08-07 21:14 ET
Gilead Sciences reported for 2025 q2
SEC form 8
2025-08-07 20:26 ET
Gilead Sciences reported for 2025 q2
SEC form 8
2025-08-07 20:26 ET
Gilead Sciences published news for 2025 q2
SEC form 8
2025-08-04 20:07 ET
Gilead Sciences published news for 2025 q2
SEC form 8
2025-08-04 20:07 ET
Gilead Sciences published news for 2025 q2
SEC form 8
2025-05-08 21:26 ET
Gilead Sciences published news for 2025 q1
SEC form 10
2025-05-07 20:32 ET
Gilead Sciences published news for 2025 q1
SEC form 10
2025-05-07 00:00 ET
Gilead Sciences published news for 2025 q1
SEC form 8
2025-04-24 20:03 ET
Gilead Sciences reported for 2025 q1
SEC form 8
2025-04-24 20:03 ET
Gilead Sciences published news for 2025 q1
SEC form 10
2025-02-28 21:21 ET
Gilead Sciences published news for 2024 q4
SEC form 10
2025-02-28 00:00 ET
Gilead Sciences published news for 2024 q4
SEC form 8
2025-02-11 00:00 ET
Gilead Sciences published news for 2024 q4
SEC form 8
2025-02-11 00:00 ET
Gilead Sciences reported for 2024 q4
SEC form 10
2024-11-12 08:36 ET
Gilead Sciences reported for 2024 q3
SEC form 10
2024-11-12 00:00 ET
Gilead Sciences reported for 2024 q3
SEC form 8
2024-11-06 16:09 ET
Gilead Sciences published news for 2024 q3
SEC form 8
2024-11-06 16:09 ET
Gilead Sciences reported for 2024 q3
SEC form 10
2024-08-08 17:17 ET
Gilead Sciences reported for 2024 q2
SEC form 8
2024-08-08 16:06 ET
Gilead Sciences published news for 2024 q2
SEC form 8
2024-08-08 16:06 ET
Gilead Sciences reported for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Gilead Sciences reported for 2024 q2
SEC form 10
2024-05-08 00:00 ET
Gilead Sciences published news for 2024 q1
SEC form 8
2024-04-25 16:04 ET
Gilead Sciences reported for 2024 q1
SEC form 8
2024-04-25 16:04 ET
Gilead Sciences published news for 2024 q1
SEC form 10
2024-02-23 00:00 ET
Gilead Sciences published news for 2023 q4
SEC form 8
2024-02-06 00:00 ET
Gilead Sciences published news for 2023 q4
SEC form 8
2024-02-06 00:00 ET
Gilead Sciences published news for 2023 q4
SEC form 10
2023-11-07 17:18 ET
Gilead Sciences published news for 2023 q3
SEC form 8
2023-11-07 16:03 ET
Gilead Sciences reported for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Gilead Sciences published news for 2023 q3
SEC form 10
2023-08-04 16:06 ET
Gilead Sciences published news for 2023 q2
SEC form 10
2023-08-04 00:00 ET
Gilead Sciences published news for 2023 q2
SEC form 6
2023-08-03 16:07 ET
Gilead Sciences reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Gilead Sciences published news for 2023 q2
SEC form 10
2023-05-03 00:00 ET
Gilead Sciences published news for 2023 q1
SEC form 8
2023-04-27 00:00 ET
Gilead Sciences published news for 2023 q1
SEC form 10
2023-02-22 16:18 ET
Gilead Sciences reported for 2022 q4
SEC form 10
2023-02-22 00:00 ET
Gilead Sciences reported for 2022 q4
SEC form 6
2023-02-06 16:06 ET
Gilead Sciences published news for 2022 q4
SEC form 6
2023-02-02 16:03 ET
Gilead Sciences published news for 2022 q4
SEC form 8
2023-02-02 00:00 ET
Gilead Sciences reported for 2022 q4
SEC form 10
2022-11-02 17:02 ET
Gilead Sciences reported for 2022 q3
SEC form 10
2022-11-02 00:00 ET
Gilead Sciences reported for 2022 q3
SEC form 6
2022-10-27 16:04 ET
Gilead Sciences published news for 2022 q3
SEC form 8
2022-10-27 00:00 ET
Gilead Sciences reported for 2022 q3
SEC form 6
2022-09-12 08:00 ET
Gilead Sciences published news for 2022 q2
SEC form 10
2022-08-08 16:43 ET
Gilead Sciences reported for 2022 q2
SEC form 10
2022-08-08 00:00 ET
Gilead Sciences reported for 2022 q2
SEC form 6
2022-08-02 16:05 ET
Gilead Sciences published news for 2022 q2
SEC form 8
2022-08-02 00:00 ET
Gilead Sciences reported for 2022 q2
SEC form 6
2022-07-28 16:01 ET
Gilead Sciences published news for 2022 q2
SEC form 6
2022-05-31 16:01 ET
Gilead Sciences published news for 2022 q1
SEC form 6
2022-05-05 16:01 ET
Gilead Sciences published news for 2022 q1
SEC form 10
2022-05-04 16:26 ET
Gilead Sciences reported for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Gilead Sciences reported for 2022 q1
SEC form 6
2022-04-28 16:07 ET
Gilead Sciences published news for 2022 q1
SEC form 8
2022-04-28 00:00 ET
Gilead Sciences reported for 2022 q1
SEC form 6
2022-03-24 16:03 ET
Gilead Sciences published news for 2021 q4
SEC form 6
2022-03-07 08:30 ET
Gilead Sciences published news for 2021 q4
SEC form 10
2022-02-23 16:55 ET
Gilead Sciences published news for 2021 q4
SEC form 10
2022-02-23 00:00 ET
Gilead Sciences published news for 2021 q4
SEC form 6
2022-02-01 16:07 ET
Gilead Sciences published news for 2021 q4
SEC form 6
2022-02-01 16:03 ET
Gilead Sciences published news for 2021 q4
SEC form 8
2022-02-01 00:00 ET
Gilead Sciences published news for 2021 q4
SEC form 8
2022-02-01 00:00 ET
Gilead Sciences published news for 2021 q4
SEC form 6
2022-01-06 16:30 ET
Gilead Sciences published news for 2021 q4
SEC form 10
2021-11-03 16:30 ET
Gilead Sciences published news for 2021 q3
SEC form 10
2021-11-03 00:00 ET
Gilead Sciences published news for 2021 q3
SEC form 6
2021-10-28 16:09 ET
Gilead Sciences published news for 2021 q3
SEC form 8
2021-10-28 00:00 ET
Gilead Sciences published news for 2021 q3
SEC form 10
2021-08-05 16:09 ET
Gilead Sciences published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Gilead Sciences published news for 2021 q2
SEC form 6
2021-07-29 16:05 ET
Gilead Sciences published news for 2021 q2
SEC form 8
2021-07-29 00:00 ET
Gilead Sciences published news for 2021 q2
SEC form 6
2021-05-14 15:04 ET
Gilead Sciences published news for 2021 q1
SEC form 10
2021-05-06 16:11 ET
Gilead Sciences published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Gilead Sciences published news for 2021 q1
SEC form 6
2021-04-29 16:06 ET
Gilead Sciences published news for 2021 q1
SEC form 8
2021-04-29 00:00 ET
Gilead Sciences published news for 2021 q1
SEC form 6
2021-03-30 16:39 ET
Gilead Sciences published news for 2020 q4
SEC form 10
2021-02-25 16:15 ET
Gilead Sciences published news for 2020 q4
SEC form 6
2021-02-04 16:05 ET
Gilead Sciences published news for 2020 q4
SEC form 6
2021-01-11 06:04 ET
Gilead Sciences published news for 2020 q4
SEC form 6
2021-01-06 17:25 ET
Gilead Sciences published news for 2020 q4
SEC form 6
2020-12-08 16:14 ET
Gilead Sciences published news for 2020 q3
SEC form 10
2020-11-03 19:12 ET
Gilead Sciences published news for 2020 q3
SEC form 6
2020-10-28 16:09 ET
Gilead Sciences published news for 2020 q3
SEC form 6
2020-10-23 17:12 ET
Gilead Sciences published news for 2020 q3
SEC form 6
2020-10-22 12:34 ET
Gilead Sciences published news for 2020 q3
SEC form 6
2020-09-30 08:19 ET
Gilead Sciences published news for 2020 q2